NASDAQ: INTSIntensity Therapeutics Inc Stock Ownership - Who owns Intensity Therapeutics?
Insider buying vs selling
Have Intensity Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Joseph Talamo | Chief Financial Officer | 2026-06-30 | 1,093 | $3.49 | $3.81kBuy |
| John M. Wesolowski | Principal Accounting Officer | 2026-06-30 | 3,688 | $3.49 | $12.85kBuy |
| Lewis H. Bender | President and CEO | 2026-03-26 | 37,749 | $6.11 | $230.65kBuy |
| Joseph Talamo | Chief Financial Officer | 2025-12-31 | 14,482 | $0.26 | $3.79kBuy |
| John M. Wesolowski | Principal Accounting Officer | 2025-12-31 | 8,918 | $0.26 | $2.34kBuy |
INTS insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when INTS insiders and whales buy or sell their stock.
INTS Shareholders
What type of owners hold Intensity Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Lewis H. Bender | 4.39% | 118,549 | $502.65k | Insider |
| Geode Capital Management LLC | 0.96% | 26,019 | $110.32k | Institution |
| Sapient Capital LLC | 0.96% | 26,006 | $110.27k | Institution |
| Nano Cap New Millennium Growth Fund L P | 0.92% | 25,000 | $106.00k | Institution |
| Rothschild Wealth LLC | 0.86% | 23,294 | $98.77k | Institution |
| Vanguard Capital Management LLC | 0.62% | 16,841 | $71.41k | Institution |
| Mesirow Financial Investment Management Inc | 0.52% | 14,118 | $59.86k | Institution |
| Vanguard Fiduciary Trust Co | 0.34% | 9,121 | $38.67k | Institution |
| John M. Wesolowski | 0.26% | 7,102 | $30.11k | Insider |
| Joseph Talamo | 0.08% | 2,239 | $9.49k | Insider |
INTS vs Biotech Stocks
Intensity Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.